Literature DB >> 23714734

Poly(ADP-ribosyl)ation in carcinogenesis.

Mitsuko Masutani1, Hiroaki Fujimori.   

Abstract

Cancer develops through diverse genetic, epigenetic and other changes, so-called 'multi-step carcinogenesis', and each cancer harbors different alterations and properties. Here in this article we review how poly(ADP-ribosyl)ation is involved in multi-step and diverse pathways of carcinogenesis. Involvement of poly- and mono-ADP-ribosylation in carcinogenesis has been studied at molecular and cellular levels, and further by animal models and human genetic approaches. PolyADP-ribosylation acts in DNA damage repair response and maintenance mechanisms of genomic stability. Several DNA repair pathways, including base-excision repair and double strand break repair pathways, involve PARP and PARG functions. These care-taker functions of poly(ADP-ribosyl)ation suggest that polyADP-ribosyation may mainly act in a tumor suppressive manner because genomic instability caused by defective DNA repair response could serve as a driving force for tumor progression, leading to invasion, metastasis and relapse of cancer. On the other hand, the new concept of 'synthetic lethality by PARP inhibition' suggests the significance of PARP activities for survival of cancer cells that harbor defects in DNA repair. Accumulating evidence has revealed that some PARP family molecules are involved in various signaling cascades other than DNA repair, including epigenetic and transcriptional regulations, inflammation/immune response and epithelial-mesenchymal transition, suggesting that poly(ADP-ribosyl)ation both promotes and suppresses carcinogenic processes depending on the conditions. Expanding understanding of poly(ADP-ribosyl)ation suggests that strategies to achieve cancer prevention targeting poly(ADP-ribosyl)ation for genome protection against life-long exposure to environmental carcinogens and endogenous carcinogenic stimuli.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23714734     DOI: 10.1016/j.mam.2013.05.003

Source DB:  PubMed          Journal:  Mol Aspects Med        ISSN: 0098-2997


  21 in total

Review 1.  Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.

Authors:  Nathan A Berger; Valerie C Besson; A Hamid Boulares; Alexander Bürkle; Alberto Chiarugi; Robert S Clark; Nicola J Curtin; Salvatore Cuzzocrea; Ted M Dawson; Valina L Dawson; György Haskó; Lucas Liaudet; Flavio Moroni; Pál Pacher; Peter Radermacher; Andrew L Salzman; Solomon H Snyder; Francisco Garcia Soriano; Robert P Strosznajder; Balázs Sümegi; Raymond A Swanson; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2017-03-26       Impact factor: 8.739

Review 2.  Emerging roles of ADP-ribosyl-acceptor hydrolases (ARHs) in tumorigenesis and cell death pathways.

Authors:  Xiangning Bu; Jiro Kato; Joel Moss
Journal:  Biochem Pharmacol       Date:  2018-09-27       Impact factor: 5.858

Review 3.  Trial watch - inhibiting PARP enzymes for anticancer therapy.

Authors:  Antonella Sistigu; Gwenola Manic; Florine Obrist; Ilio Vitale
Journal:  Mol Cell Oncol       Date:  2015-06-10

4.  MDC1 promotes ovarian cancer metastasis by inducing epithelial-mesenchymal transition.

Authors:  Xiaolin Liu; Ruifen Dong; Zhijun Jiang; Yuyan Wei; Yingwei Li; Linxuan Wei; Hengzi Sun; Yinuo Li; Ning Yang; Qifeng Yang; Zhaojian Liu; Beihua Kong
Journal:  Tumour Biol       Date:  2015-01-16

Review 5.  Research Progress on Mono-ADP-Ribosyltransferases in Human Cell Biology.

Authors:  Yujie Gan; Huanhuan Sha; Renrui Zou; Miao Xu; Yuan Zhang; Jifeng Feng; Jianzhong Wu
Journal:  Front Cell Dev Biol       Date:  2022-05-16

6.  Identifying Family-Member-Specific Targets of Mono-ARTDs by Using a Chemical Genetics Approach.

Authors:  Ian Carter-O'Connell; Haihong Jin; Rory K Morgan; Roko Zaja; Larry L David; Ivan Ahel; Michael S Cohen
Journal:  Cell Rep       Date:  2016-01-07       Impact factor: 9.423

7.  Clinical significance of serum ADP-ribosylation and NAD glycohydrolase activity in patients with colorectal cancer.

Authors:  Başak Varol; Özlem Coşkun; Senem Karabulut; Kürşat Rahmi Serin; Oktar Asoğlu; Işıl Albeniz; Faruk Taş; Rüstem Nurten
Journal:  Tumour Biol       Date:  2014-02-18

8.  PARP inhibitor ABT-888 affects response of MDA-MB-231 cells to doxorubicin treatment, targeting Snail expression.

Authors:  Germano Mariano; Maria Rosaria Ricciardi; Daniela Trisciuoglio; Michele Zampieri; Fabio Ciccarone; Tiziana Guastafierro; Roberta Calabrese; Elisabetta Valentini; Agostino Tafuri; Donatella Del Bufalo; Paola Caiafa; Anna Reale
Journal:  Oncotarget       Date:  2015-06-20

Review 9.  Roles of NAD (+) , PARP-1, and Sirtuins in Cell Death, Ischemic Brain Injury, and Synchrotron Radiation X-Ray-Induced Tissue Injury.

Authors:  Weihai Ying
Journal:  Scientifica (Cairo)       Date:  2013-12-10

10.  Fish oil administration mediates apoptosis of Walker 256 tumor cells by modulation of p53, Bcl-2, caspase-7 and caspase-3 protein expression.

Authors:  Gina Borghetti; Adriana Aya Yamaguchi; Julia Aikawa; Ricardo Key Yamazaki; Gleisson Alisson Pereira de Brito; Luiz Claudio Fernandes
Journal:  Lipids Health Dis       Date:  2015-08-25       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.